These results indicated that the use of GnRH-ant in the early follicular phase did not affect the growth and ovulation of dominant follicles.[22,38] Some scholars believe that the use of GnRH-ant throughout the COS tended to improve the clinical outcome by reducing the rapid rise in serum E2 concentrations and the risk of early LH peak in patients with PCOS.[39] The present study reached a similar conclusion. Here, GNRH1 is linked to polycystic ovary syndrome.